Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has appointed Julie Maltzman, M.D., as Chief Medical Officer, effective January 13, 2025.
 
Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet’s autoimmune and oncology pipeline.
 
“We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the clinical development of multiple products across therapeutic areas notably in solid tumors and autoimmune diseases, from early-stage research to global approvals and commercialization, will be a big asset for Adicet as we advance our novel pipeline of allogeneic gamma delta CAR T cell therapies for multiple autoimmune and oncology indications,” said Chen Schor, President and CEO of Adicet Bio.
 
Maltzman succeeds Dr. Francesco Galimi who completed his tenure at Adicet this month.
 
“I am extremely honored and privileged to join the Adicet team during this pivotal time in the Company’s growth trajectory,” said Maltzman. “Having worked on the development of several transformative therapies, I believe Adicet’s novel allogeneic gamma delta CAR T cell platform has life-changing potential for patients with various oncologic and autoimmune diseases. I am inspired by the opportunity to help lead our efforts to bring these therapies in development to the many patients around the globe who are in dire need of a potential new curative treatment approach.”

Experience 

Maltzman has 20 years of experience leading clinical development efforts both in oncology and autoimmune diseases across all phases of drug development, from early Phase 1 through global regulatory filings, approvals and commercialization.
 
She joins Adicet from IconOVir Bio where she served as Chief Medical Officer leading, designing, and executing on a clinical development program focused on refractory solid tumors. Prior to that, she served as the VP, Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech. There, she oversaw the successful worldwide registration and commercialization of the solid tumor combination therapy Tecentriq+Avastin and co-led the cross-functional team accountable for managing all Tecentriq program activities including manufacturing, safety, biomarker and translational research, regulatory strategy, branding and positioning. Maltzman also served as the executive Co-Chair of their multifunctional, senior-level integrated Cancer Immunotherapy Committee (CITC).
 
With additional leadership roles at flagship biopharma companies including Gilead and Glaxo SmithKline (GSK), Maltzman has designed and efficiently implemented clinical studies exceeding enrollment goals months earlier than anticipated, assisted with CMC (Chemistry, Manufacturing and Controls) initiatives to support clinical and regulatory submissions, conceptualized and negotiated multiple U.S. and EU labels, and established and built Medical and Medical Affairs functions including activating key opinion leader (KOL) and scientific educational initiatives to drive therapeutic awareness and adoption.
 
Maltzman earned her M.D. from the University of Colorado, completed her Internship and Residency in the Department of Internal Medicine at the University of Chicago, and completed a Fellowship in the Division of Hematology/Oncology at the University of Pennsylvania.